What Are the Risk Factors for Acute Myeloid Leukemia?

A risk factor is something that affects your chance of getting a disease, such as cancer. Different cancers have different risk factors. Some risk factors, like smoking, can be changed. Others, like a person’s age or family history, can’t be changed.

But having a risk factor, or even several risk factors, does not mean that you definitely will get the disease. And many people who get the disease may have few or no known risk factors. Even if a person has a risk factor and develops cancer, it’s often very hard to know how much that risk factor contributed to the cancer.

There are some known risk factors for acute myeloid leukemia (AML).


The only proven lifestyle-related risk factor for AML is smoking. Many people know that smoking is linked to cancers of the lungs, mouth, throat, and larynx (voice box), but few realize that it can also affect cells that don’t come into direct contact with smoke. Cancer-causing substances in tobacco smoke are absorbed by the lungs and spread through the bloodstream to many parts of the body.

Certain chemical exposures

The risk of AML is increased by exposure to certain chemicals.

For example, long-term exposure to high levels of benzene is a risk factor for AML. Benzene is a solvent used in the rubber industry, oil refineries, chemical plants, shoe manufacturing, and gasoline-related industries, and is also found in cigarette smoke, gasoline and motor vehicle exhaust, and some glues, cleaning products, detergents, art supplies, and paints.

Some studies have linked heavy workplace exposure to formaldehyde with AML risk, but this link has not been seen in some other studies.

Certain chemotherapy drugs

Patients with cancer who are treated with certain chemotherapy (chemo) drugs are more likely to develop AML.

Drugs called alkylating agents and platinum agents are linked to an increased risk of AML that peaks about 8 years after chemo. Often a patient will get a disease called myelodysplastic syndrome before the AML. Examples of alkylating agents include cyclophosphamide, mechlorethamine, procarbazine, chlorambucil, melphalan, busulfan, and carmustine. Platinum drugs include cisplatin and carboplatin.

Chemo drugs known as topoisomerase II inhibitors are also linked to AML. AML linked to these drugs tends to occur only a few years after treatment and without myelodysplastic syndrome developing first. Examples of topoisomerase II inhibitors include etoposide, teniposide, mitoxantrone, epirubicin, and doxorubicin.

For more information, see Second Cancers in Adults.

Radiation exposure

High-dose radiation exposure (such as being a survivor of an atomic bomb blast or nuclear reactor accident) increases the risk of developing AML. Japanese atomic bomb survivors had a greatly increased risk of developing acute leukemia, most often about 6 to 8 years after exposure.

Radiation treatment for cancer has also been linked to an increased risk of AML. The risk varies based on the amount of radiation given and what area is treated, but is not as high as was seen after the atomic bomb blasts.

The possible risks of leukemia from exposure to lower levels of radiation, such as from imaging tests like x-rays or CT scans, are not well-defined. If a fetus is exposed to radiation within the first months of development, it may carry an increased risk of leukemia, but the extent of the risk is not clear. If there is an increased risk it is likely to be small, but to be safe, most doctors try to limit radiation exposure from tests as much as possible, especially in children and pregnant women.

For more information, see X-rays, Gamma Rays and Cancer Risk.

Certain blood disorders

People with certain blood disorders seem to be at increased risk for getting AML. These include chronic myeloproliferative disorders such as polycythemia vera, essential thrombocythemia, and idiopathic myelofibrosis. The risk of AML is increased further if treatment for these disorders includes some types of chemotherapy or radiation.

Some people who have myelodysplastic syndrome (MDS) may develop AML. Patients with MDS have low blood cell counts and abnormal cells in the blood and bone marrow. MDS can evolve over time into AML. Patients who develop AML after having MDS typically have a poor prognosis.

Genetic syndromes

Some syndromes that are caused by genetic mutations (abnormal changes) present at birth seem to raise the risk of AML. These include:

  • Fanconi anemia
  • Bloom syndrome
  • Ataxia-telangiectasia
  • Diamond-Blackfan anemia
  • Schwachman-Diamond syndrome
  • Li-Fraumeni syndrome
  • Neurofibromatosis type 1
  • Severe congenital neutropenia (also called Kostmann syndrome)

Some chromosome problems present at birth are also linked to a higher risk of AML, including:

  • Down syndrome (being born with an extra copy of chromosome 21)
  • Trisomy 8 (being born with an extra copy of chromosome 8)

Family history

Although most cases of AML are not thought to have a strong genetic link, having a close relative (such as a parent or sibling) with AML increases your risk of getting the disease.

Someone who has an identical twin who got AML before they were a year old has a very high risk of also getting AML.

Older age

AML can occur at any age, but it becomes more common as people get older.

Male gender

AML is more common in males than in females. The reason for this is not clear.

Uncertain, unproven or controversial risk factors

Other factors that have been studied for a possible link to AML include:

  • Exposure to electromagnetic fields (such as living near power lines)
  • Workplace exposure to diesel, gasoline, and certain other chemicals and solvents
  • Exposure to herbicides or pesticides

So far, none of these factors has been linked conclusively to AML. Research in these areas is ongoing.

The American Cancer Society medical and editorial content team
Our team is made up of doctors and master's-prepared nurses with deep knowledge of cancer care as well as journalists, editors, and translators with extensive experience in medical writing.

Last Medical Review: December 9, 2014 Last Revised: February 22, 2016

American Cancer Society medical information is copyrighted material. For reprint requests, please see our Content Usage Policy.